Dataset Information

ARv7 Represses Tumor-Suppressor Genes in Castration-Resistant Prostate Cancer.

ABSTRACT: Androgen deprivation therapy for prostate cancer (PCa) benefits patients with early disease, but becomes ineffective as PCa progresses to a castration-resistant state (CRPC). Initially CRPC remains dependent on androgen receptor (AR) signaling, often through increased expression of full-length AR (ARfl) or expression of dominantly active splice variants such as ARv7. We show in ARv7-dependent CRPC models that ARv7 binds together with ARfl to repress transcription of a set of growth-suppressive genes. Expression of the ARv7-repressed targets and ARv7 protein expression are negatively correlated and predicts for outcome in PCa patients. Our results provide insights into the role of ARv7 in CRPC and define a set of potential biomarkers for tumors dependent on ARv7.

SUBMITTER: Cato L

PROVIDER: S-EPMC7246081 | biostudies-literature | 2019 Mar

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

ARv7 Represses Tumor-Suppressor Genes in Castration-Resistant Prostate Cancer.

Cato Laura L de Tribolet-Hardy Jonas J Lee Irene I Rottenberg Jaice T JT Coleman Ilsa I Melchers Diana D Houtman René R Xiao Tengfei T Li Wei W Uo Takuma T Sun Shihua S Kuznik Nane C NC Göppert Bettina B Ozgun Fatma F van Royen Martin E ME Houtsmuller Adriaan B AB Vadhi Raga R Rao Prakash K PK Li Lewyn L Balk Steven P SP Den Robert B RB Trock Bruce J BJ Karnes R Jeffrey RJ Jenkins Robert B RB Klein Eric A EA Davicioni Elai E Gruhl Friederike J FJ Long Henry W HW Liu X Shirley XS Cato Andrew C B ACB Lack Nathan A NA Nelson Peter S PS Plymate Stephen R SR Groner Anna C AC Brown Myles M

Cancer cell 20190214 3

Androgen deprivation therapy for prostate cancer (PCa) benefits patients with early disease, but becomes ineffective as PCa progresses to a castration-resistant state (CRPC). Initially CRPC remains dependent on androgen receptor (AR) signaling, often through increased expression of full-length AR (ARfl) or expression of dominantly active splice variants such as ARv7. We show in ARv7-dependent CRPC models that ARv7 binds together with ARfl to repress transcription of a set of growth-suppressive g ...[more]

PMID: 30773341

Dataset Information

ARv7 Represses Tumor-Suppressor Genes in Castration-Resistant Prostate Cancer.

Publications

ARv7 Represses Tumor-Suppressor Genes in Castration-Resistant Prostate Cancer.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets

Similar Datasets

ARv7 represses tumor suppressors genes in castration-resistant prostate cancer
2018-11-02 | GSE106561 | GEO

ARv7 represses tumor suppressors genes in castration-resistant prostate cancer [ChIP-Seq]
2018-11-02 | GSE106559 | GEO

ARv7 represses tumor suppressors genes in castration-resistant prostate cancer [RNA-Seq]
2018-11-02 | GSE106560 | GEO

ARv7 represses tumor suppressors genes in castration-resistant prostate cancer
| PRJNA417248 | ENA

ARv7 represses tumor suppressors genes in castration-resistant prostate cancer [ChIP-Seq]
| PRJNA417256 | ENA

ARv7 represses tumor suppressors genes in castration-resistant prostate cancer [RNA-Seq]
| PRJNA417254 | ENA

A Novel, Circulating Tumor Cell Enrichment Method Reduces ARv7 False Positivity in Patients with Castration-Resistant Prostate Cancer.
| S-EPMC7151149 | biostudies-literature

Inhibition of Plk1 represses androgen signaling pathway in castration-resistant prostate cancer.
| S-EPMC4612397 | biostudies-literature

Could Circulating Tumor Cells and ARV7 Detection Improve Clinical Decisions in Metastatic Castration-Resistant Prostate Cancer? The Istituto Nazionale dei Tumori (INT) Experience.
| S-EPMC6678845 | biostudies-literature

Analysis of AR/ARV7 Expression in Isolated Circulating Tumor Cells of Patients with Metastatic Castration-Resistant Prostate Cancer (SAKK 08/14 IMPROVE Trial).
| S-EPMC6721786 | biostudies-literature